Raymond James raises Encompass Health stock price target on strong results
Raymond James raised its price target for Encompass Health (EHC) to $155 from $150, citing strong Q3 results and raised guidance. The company beat EBITDA expectations for the 16th straight quarter, driven by acuity and cost control. EHC shares are near their 52-week high, up 32% in six months. Analysts like UBS, KeyBanc, and Truist also raised their price targets, noting strong EBITDA performance and positive 2027 outlook.
How this was made
The 30-second read
Why it matters
Analyst upgrades and raised guidance suggest a bullish short‑term outlook for the stock.
Market read
Earnings beat and upgraded price targets provide a fresh catalyst for EHC, likely driving buying interest.
What to watch
Potential policy changes to Medicaid or payment caps could affect future earnings.
Background
Encompass Health reported Q3 adjusted EPS of $1.52 vs $1.36 estimate and revenue of $1.61 B, beating expectations and prompting several broker upgrades.
Ticker impact
Raymond James raised its price target on Encompass Health (EHC) to $155 after the company reported a Q3 earnings beat and raised guidance.
likely upward pressure as investors price in higher target and guidance
Multiple brokerages lifted price targets on fresh Q3 results, indicating fresh bullish sentiment.
Market effects
Strong performance may lift other inpatient rehab and healthcare providers.
U.S. healthcare sector could see modest gains.
Limited to U.S. equities; no broader macro impact.
Counterpoint
Valuation appears stretched versus fair value; price may correct if growth slows.
Key entities
- companyEncompass Health Corp
U.S. provider of inpatient rehabilitation services.
- analystRaymond James
Raised price target to $155, maintaining Strong Buy.
